Navigation Links
Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
Date:5/18/2009

and the consideration within the specified range of Exchange Consideration at which they wish to tender such Notes.

As of May 18, 2009, approximately $118.9 million aggregate principal amount of the Notes was outstanding. The Exchange Offer is conditioned upon a minimum of $83,260,100 aggregate principal amount of Notes being validly tendered and not withdrawn, as well as certain other terms and conditions described in the Company's Offer to Exchange, dated May 12, 2009 (as supplement May 19, 2009, the "Offer to Exchange"), the related Amended and Restated Letter of Transmittal, and other related Exchange Offer materials (which collectively, as may be amended, restated, supplemented, or otherwise modified from time to time, constitute the "Exchange Offer Documents").

The Exchange Offer is scheduled to expire at 5:00 p.m., New York City time, on Wednesday, June 10, 2009, unless the Exchange Offer is extended. Tendered Notes may be withdrawn at any time on or prior to the expiration date of the Exchange Offer.

CTI is conducting the Exchange Offer in order to reduce the principal amount of its outstanding indebtedness. CTI believes that reducing its outstanding indebtedness is necessary in order for its business to operate in light of its current asset base and revenue prospects.

If the aggregate amount of Notes validly tendered and not properly withdrawn on or prior to the expiration date at or below the Exchange Consideration exceeds the amount CTI is offering to exchange, CTI will accept for payment the Notes that are validly tendered and not properly withdrawn from the Exchange Offer at or below the Exchange Consideration on a pro rata basis from among the tendered Notes.

The financial advisor for the Exchange Offer is Piper Jaffray & Co., the information agent for the Exchange Offer is Georgeson Inc. and the depositary for the Exchange Offer is U.S. Bank National Associati
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
2. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
3. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Orexigen(R) Therapeutics to Present at Upcoming Meetings
6. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
7. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
8. PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration
9. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
10. Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
11. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 MabVax Therapeutics Holdings, Inc. (OTCQB: ... the Company,s lead antibody, HuMab 5B1, will be garnering ... during the upcoming World Molecular Imaging Congress (WMIC) being ... 2015. Researchers from the Department of Radiology at Memorial ... the use of MabVax,s lead antibody as a PET ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) has announced ... - Growth, Trends & Forecasts (2014-2020)" report to ... Sensors market is estimated at $0.20 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Middle East & Africa Biomedical Sensors Market ... their offering. The Middle ... estimated at $0.84 billion by 2018 at a CAGR ... near future will bring Biomedical sensors that are adaptable ...
(Date:8/31/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... pleased to announce that its wholly owned subsidiary, Portage ... PPL-003, to an Investigational New Drug (IND) application for ... PPL recently completed a study in a rat model ... highly significant efficacy and a more rapid onset of ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Mexico Biomedical Sensors Market Report 2015-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3
... FRANCISCO, Calif., May 8 Anesiva,Inc. (Nasdaq: ... and accomplishments,for the first quarter ended March ... its,commercialization activities for FDA-approved Zingo(TM) (lidocaine,hydrochloride monohydrate) ... development milestones for Adlea(TM), the company,s long-acting,localized, ...
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a ... to participate in the Bank of America,2008 Health ... in Las Vegas,Nevada., Dr. William Hunter, Angiotech,s ... on Wednesday, May 14, beginning at approximately,4:00 pm ...
... highlights Volcano commitment to intravascular imaging ... opens up new clinical and research applications, ... Corporation (Nasdaq: VOLC ), a leading manufacturer ... and Optical,Coherence Tomography (OCT) products designed to enhance ...
Cached Biology Technology:Anesiva Announces First Quarter 2008 Financial Results 2Anesiva Announces First Quarter 2008 Financial Results 3Anesiva Announces First Quarter 2008 Financial Results 4Anesiva Announces First Quarter 2008 Financial Results 5Anesiva Announces First Quarter 2008 Financial Results 6Anesiva Announces First Quarter 2008 Financial Results 7Anesiva Announces First Quarter 2008 Financial Results 8Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 2Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 3Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 4
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/12/2015)... Minn. , Aug. 12, 2015   MedNet ... supports the entire spectrum of clinical research, is proud ... , the company,s comprehensive SaaS-based eClinical technology platform, has ... during the first two quarters of 2015.   Q2 ... second largest quarters measured by contract value sold in ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... This release is available in German . ... To defend themselves, they have developed sophisticated chemical defense ... cress ( Arabidopsis thaliana ), produce glucosinolates (mustard oil ... different kinds of these molecules; they have a similar ...
... such as the Japan earthquake can be revealed in ... to a psychology expert at Queen Mary, University of ... Mary, University of London, and author of Controlling Uncertainty: ... had a devastating immediate effect on tens of thousands ...
... Using skin cells from adult siblings with schizophrenia and ... researchers have created induced pluripotent stem cells (iPS cells) using ... February 22 in Molecular Psychiatry , the team confirms ... mutations in the gene named Disrupted In Schizophrenia 1, or ...
Cached Biology News:Production of mustard oils: On the origin of an enzyme 2Production of mustard oils: On the origin of an enzyme 3Psychological impact of Japan disaster will be felt 'for some time to come' 2Johns Hopkins team creates stem cells from schizophrenia patients 2Johns Hopkins team creates stem cells from schizophrenia patients 3
NATIVE, ENZYME PORCINE TRYPSIN...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Alkaline Phosphatase Stabilizer Solution, 1 L...
Biology Products: